← Back to headlines
Summit Therapeutics Lung Cancer Drug Shows Significant Survival Benefits in Trial Data
Clinical trial results indicate that Summit Therapeutics’ investigational drug ivonescimab meets key secondary endpoints for overall survival in non-small cell lung cancer patients. The promising interim data positions the treatment as a potential new standard in first-line therapy.
2 Sept, 21:00 — 2 Sept, 22:09
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (27/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left
Center1
Center (1)
morningstar
Right1
Right (1)
seeking-alpha
Far R
Geographic diversity— 1 region4/34
US2
ℹAll sources from US region
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
morningstar20h ago
Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC - Morningstar
Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC Morningstar
Read full article →seeking-alphaMixed19h ago
Summit Therapeutics in focus as its lung cancer drug shows survival benefit
Read full article →Coverage Timeline
First report: morningstar · 2 Sept, 21:00|Full coverage: 2 · 1h|Window: 1h
Left-leaningCenterRight-leaning
